Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

PURE Bioscience (PURE) had Revenue of $1.96M for the most recently reported fiscal year, ending 2024-07-31.

Quarterly Annual

Figures for fiscal year ending 2024-07-31

Income Statement Financials
Revenue	$1.96M
Net Income	$-3.35M
Cost of Goods Sold	$0.81M
Gross Profit	$1.15M
Operating Expenses	$5.15M
Operating Income	$-3.19M
Non-Operating Income/Expense	$-0.16M
Pre-Tax Income	$-3.35M
Normalized Pre-Tax Income	$-3.35M
Income after Taxes	$-3.35M
Income from Continuous Operations	$-3.35M
Consolidated Net Income/Loss	$-3.35M
Normalized Income after Taxes	$-3.35M
EBIT	$-3.19M
EBITDA	$-3.04M
Weighted-Average Shares Outstanding (Basic)	111.86M
Weighted-Average Shares Outstanding (Diluted)	111.86M
Earnings per Share (EPS) (Basic)	$-0.03
Earnings per Share (EPS) (Diluted)	$-0.03
Balance Sheet Financials
Current Assets	$0.81M
Property, Plant, and Equipment	$0.01M
Long-Term Assets	$0.01M
Total Assets	$0.82M
Current Liabilities	$0.73M
Long-Term Debt	$2.95M
Long-Term Liabilities	$2.95M
Total Liabilities	$3.68M
Common Equity	$-2.86M
Tangible Shareholders Equity	$-2.86M
Shareholders Equity	$-2.86M
Common Shares Outstanding	111.86M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-2.53M
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	$1.78M
Beginning Cash	$1.17M
End Cash	$0.42M
Increase/Decrease in Cash	$-0.75M
Stock-Based Compensation	$0.21M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.10
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	34.69
Debt to Equity Ratio	-1.03
Gross Margin	58.69%
Operating Margin	-162.56%
EBIT Margin	-162.56%
EBITDA Margin	-155.02%
Pre-Tax Profit Margin	-170.66%
Profit Margin	-170.66%
Free Cash Flow	$-2.53M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	2.40
Inventory Turnover	14.48
Receiveable Turnover	6.59
Days Sales in Receivables	55.41
Return on Equity	116.97%
Return on Tangible Equity	116.97%
Return on Assets	-409.54%
Return on Investments	-3941.19%
Book Value Per Share	$-0.03
Free Cash Flow per Share	$-0.02
Operating Cash Flow per Share	$-0.02

Data from Zacks Investment Research, Inc.